Spironolactone for Hair Loss: The Anti-Androgen Women Need to Know About

Spironolactone is the most commonly prescribed anti-androgen for women's hair loss in the United States — and until 2025, it didn't have a single randomized, placebo-controlled trial to prove it worked. That just changed. A landmark RCT published in the International Journal of Women's Dermatology finally provides the rigorous evidence dermatologists have been prescribing ahead of for decades.

This guide is part of our comprehensive women's hair loss series. Here, we go deep on spironolactone specifically: how it works, what the evidence actually shows, dosing protocols, side effects, and who it's best suited for.

How Spironolactone Works for Hair Loss

Spironolactone was originally developed as a potassium-sparing diuretic for treating high blood pressure and heart failure. But it has a secondary mechanism that makes it invaluable for women's hair loss: it's an androgen receptor blocker.

Here's the pharmacology in plain language: androgens (like testosterone and DHT) bind to receptors in your hair follicles and trigger miniaturization — causing hair to become progressively thinner and shorter until it's barely visible. Spironolactone competitively blocks those receptors, preventing androgens from reaching the follicle. It also reduces androgen production in the ovaries and adrenal glands. The result: less hormonal pressure on your hair follicles.

This is fundamentally different from how minoxidil works. Minoxidil stimulates growth regardless of the cause. Spironolactone addresses the hormonal root cause of androgenetic hair loss. That's why the two treatments are frequently combined — they attack the problem from different angles.

The Clinical Evidence (2025 Update)

Systematic Review and Meta-Analysis (2023)

A comprehensive meta-analysis across 4 studies and 192 patients found:

• Overall improvement rate: 56.6% (95% CI: 40.5–71.4%)
• Combined therapy (spiro + minoxidil): 65.8% improvement
• Monotherapy (spiro alone): 43.2% improvement
• No improvement or modest improvement: 37.8%
• Adverse event rate overall: 3.7% (drug discontinuation: 2.8%)

The takeaway: spironolactone works significantly better when combined with minoxidil than when used alone. If you're considering spironolactone, plan to use it as an addition to — not a replacement for — topical or oral minoxidil.

The 100-Women Pilot Study

An earlier pilot study by Sinclair (2018) treated 100 women with a daily capsule containing oral minoxidil 0.25mg + spironolactone 25mg — much lower doses than typically prescribed. Mean hair loss severity improved by 0.85 points on the Sinclair scale at 6 months and 1.3 points at 12 months, with corresponding reductions in shedding. This low-dose combination approach is gaining popularity because it offers both mechanisms (growth stimulation + androgen blocking) with fewer side effects.

Dosing: What Dermatologists Actually Prescribe

Most dermatologists start at 100mg/day, taken once daily (some split into 50mg twice daily). Effects typically become noticeable at 6 months, with continued improvement through 12+ months. Two-thirds of patients in one study achieved their best results at 12 months or longer, so patience is essential.

Side Effects: What to Expect

Who Spironolactone Is Best For

• Women with FPHL who haven't responded adequately to minoxidil alone — the meta-analysis shows the combination is significantly more effective than either treatment alone
• Women with signs of hyperandrogenism — acne, hirsutism, or irregular periods alongside hair thinning, particularly those with PCOS
• Premenopausal women who can use reliable contraception — the 2025 RCT specifically validated its use in this population
• Postmenopausal women — no pregnancy risk, so fewer safety concerns; can be combined with topical or oral minoxidil
• Women who want an oral medication — easier compliance than twice-daily topical applications

Who Should NOT Take Spironolactone

• Women who are pregnant, planning to become pregnant, or breastfeeding
• Women with kidney disease or hyperkalemia
• Women taking potassium supplements or potassium-sparing diuretics
• Women with Addison's disease
• Women taking ACE inhibitors or ARBs (increased hyperkalemia risk — discuss with provider)

Spironolactone vs. Other Anti-Androgens

Spironolactone vs. finasteride for women: Finasteride blocks DHT production (a 5-alpha-reductase inhibitor), while spironolactone blocks the androgen receptor directly. Finasteride is not FDA-approved for women and is absolutely contraindicated in premenopausal women due to the same Category X pregnancy concerns. Some dermatologists prescribe finasteride off-label for postmenopausal women. Spironolactone has broader anti-androgenic activity and is the preferred first-line anti-androgen for premenopausal women.

Spironolactone vs. cyproterone acetate: Cyproterone acetate is a more potent anti-androgen widely used in Europe and Australia, but it's not available in the United States. One study found high-dose spironolactone (200mg) was as effective as cyproterone acetate. Spironolactone is the standard anti-androgen for women's hair loss in the US.

The Bottom Line

Spironolactone is no longer an evidence-free off-label gamble — the 2025 RCT and 2023 meta-analysis provide solid clinical support for its use in women's hair loss. Combined with minoxidil, it offers a 65.8% improvement rate with a low discontinuation rate (2.8%). Most side effects are manageable, with menstrual irregularities being the most common.

The key to success: combine it with minoxidil, be patient (6–12 months minimum), and work with a provider who can monitor your potassium levels and adjust dosing as needed. For most premenopausal women with FPHL, spironolactone + minoxidil is currently the most evidence-supported combination therapy available.